The gut-liver-kidney-brain axis in Wilson disease: copper speciation-flux and barrier-mediated organ crosstalk - Top-Institutions - MDSpire

The gut-liver-kidney-brain axis in Wilson disease: copper speciation-flux and barrier-mediated organ crosstalk

  • By

  • Nannan Qian

  • Sihuan Zhu

  • Yuqi Song

  • Yulong Yang

  • Han Wang

  • Hui Han

  • Guocun Xu

  • Wenjie Hao

  • Hailin Jiang

  • Yue Yang

  • Hu Xi

  • Yufeng Ding

  • Wei He

  • Taohua Wei

  • Wenming Yang

  • Ting Cheng

  • June 17, 2026

  • 0 min

Share

Top Institutions in Gastroenterology

Brief introduction explaining scope and methodology.

  • #1

    Yale University/Yale New Haven Hospital
    Yale University/Yale New Haven Hospital

    New Haven, Connecticut

    Key Differentiators

    • Gastroenterology
    • Hepatology

  • #2

    Miller School of Medicine, University of Miami
    Miller School of Medicine, University of Miami

    Miami, Florida

    Key Differentiators

    • Gastroenterology

  • #3

    Massachusetts General Hospital
    Massachusetts General Hospital

    Boston, Massachusetts

    Key Differentiators

    • Gastroenterology

  • #4

    Harvard Medical School
    Harvard Medical School

    Boston, Massachusetts

    Key Differentiators

    • Gastroenterology

  • #5

    Tufts University School of Medicine
    Tufts University School of Medicine

    Boston, Massachusetts

    Key Differentiators

    • Gastroenterology

Original Source(s)

The gut-liver-kidney-brain axis in Wilson disease: copper speciation-flux and barrier-mediated organ crosstalk

  • by Nannan Qian, Sihuan Zhu, Yuqi Song, Yulong Yang, Han Wang, Hui Han, Guocun Xu, Wenjie Hao, Hailin Jiang, Yue Yang, Hu Xi, Yufeng Ding, Wei He, Taohua Wei, Wenming Yang, Ting Cheng

  • June 17, 2026

Related Content

3 Innovations Revolutionizing IBD Treatment

Keck Medicine of USC gastroenterologist Florence-Damilola (Damie) Odufalu, MD, shares how recent advances in inflammatory bowel disease treatment are changing the lives of patients.

  • by

  • May 26, 2026

  • 5 min
Commentary: SEMA3B is associated with disease activity and infliximab response in IBD patients but does not contribute to the development of intestinal inflammation in vivo

Noncanonical NF-κB pathway driven inflammation across multiple cellular compartments identifies NIK as a therapeutic target for inflammatory bowel disease